Sign In
Buy VIR
$8.66
-0.240 (-2.70%)
At Close: Jul 31, 2026
Vir Biotechnology (VIR) Down on Influenza Study Failure
01:42pm, Friday, 21'st Jul 2023
Vir Biotechnology (VIR) crashes after the phase II study evaluating VIR-2482 for preventing symptomatic influenza A illness fails to meet goals.
Vir Biotech slumps to over 3-year low as flu prevention therapy fails trial
12:37pm, Thursday, 20'th Jul 2023
Vir Biotechnology's shares plunged 45% to a more than three-year low on Thursday after the company's experimental antibody therapy to prevent a type of flu failed to meet its goals in a mid-stage tria
Why Shares of Vir Biotechnology Are Plunging Thursday
11:31am, Thursday, 20'th Jul 2023
Vir Biotechnology has seen declining revenue because sales of its one marketed product, Sotrovimab, are declining. A phase 2 trial for an influenza A therapy didn't meet primary or secondary endpoints
Vir Biotechnology says mid-stage trial of a flu treatment failed to meet main goals
08:10am, Thursday, 20'th Jul 2023
Vir Biotechnology Inc. VIR, +0.92% said Thursday a mid-stage trial of a treatment for symptomatic flu failed to meet its main goals. The Phase 2 trial dubbed Peninsula was evaluating VIR-2482 for the
Vir Biotechnology to Participate in the 44th Annual Goldman Sachs Global Healthcare Conference
04:05pm, Monday, 05'th Jun 2023
SAN FRANCISCO, June 05, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, is scheduled to participate
Vir Biotechnology, Inc. (VIR) Reports Q1 Loss, Tops Revenue Estimates
09:17pm, Thursday, 04'th May 2023
Vir Biotechnology, Inc. (VIR) came out with a quarterly loss of $1.06 per share versus the Zacks Consensus Estimate of a loss of $0.81. This compares to earnings of $3.85 per share a year ago.
7 Thrilling Biotech Stocks for Aggressive Investors to Buy
01:40pm, Wednesday, 05'th Apr 2023
While it might be difficult to navigate the equities sector now amid various headwinds, biotech stocks to buy may offer a surprising respite. True, the market presence of the surprise production cuts
Is the Options Market Predicting a Spike in Vir Biotechnology (VIR) Stock?
09:59am, Wednesday, 29'th Mar 2023
Investors need to pay close attention to Vir Biotechnology (VIR) stock based on the movements in the options market lately.
Vir Biotechnology to Participate in the Barclays Global Healthcare Conference
04:05pm, Wednesday, 08'th Mar 2023
SAN FRANCISCO, March 08, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Phil Pang, M.D., Ph.D., Executive Vice President, Chief Medical Officer and Interim Head of
The Top 7 Growth Stocks in Biotech
06:57pm, Friday, 03'rd Mar 2023
Biotech stocks almost always have the potential for significant growth over time. Companies in the sector operate in areas including drug development, medical devices, and diagnostics.
Vir Biotechnology, Inc. (VIR) Reports Q4 Loss, Misses Revenue Estimates
06:49pm, Thursday, 23'rd Feb 2023
Vir Biotechnology, Inc. (VIR) delivered earnings and revenue surprises of -1,800% and 80.07%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the st
This biotech stock could double from here: Goldman Sachs
02:02pm, Tuesday, 21'st Feb 2023
Vir Biotechnology Inc (NASDAQ: VIR) jumped nearly 10% this morning after a Goldman Sachs analyst turned super bullish on the clinical-stage immunology company.
The 7 Most Undervalued Biotech Stocks to Buy in February 2023
02:19pm, Thursday, 02'nd Feb 2023
You don't have to be particularly astute to recognize the importance of the most undervalued biotech stocks to buy. Fundamentally, the enterprises that undergird these names operate on the cutting edg
GSK's Beats on Q4 Earnings & Sales, Issues Upbeat 2023 Outlook
12:02pm, Wednesday, 01'st Feb 2023
GSK's (GSK) revenues benefit from strong growth in sales across all segments, especially Shingrix vaccine sales. The company also issues fresh 2023 guidance for all its segments.
Vir Biotechnology, Inc. (VIR) Moves to Strong Buy: Rationale Behind the Upgrade
01:33pm, Tuesday, 24'th Jan 2023
Vir Biotechnology, Inc. (VIR) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
